Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 23770244)

1.

PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription.

Wierer M, Verde G, Pisano P, Molina H, Font-Mateu J, Di Croce L, Beato M.

Cell Rep. 2013 Jun 27;3(6):2021-32. doi: 10.1016/j.celrep.2013.05.024. Epub 2013 Jun 13.

2.

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL.

Cancer Res. 2015 Jan 15;75(2):405-14. doi: 10.1158/0008-5472.CAN-14-2475. Epub 2014 Dec 5.

PMID:
25480943
4.

Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.

Nilsson EM, Brokken LJ, Narvi E, Kallio MJ, Härkönen PL.

Mol Cell Endocrinol. 2012 Jul 6;358(1):104-15. doi: 10.1016/j.mce.2012.03.009. Epub 2012 Mar 23.

PMID:
22465097
5.

Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.

Lin YC, Sun SH, Wang FF.

Cell Signal. 2011 Nov;23(11):1816-23. doi: 10.1016/j.cellsig.2011.06.016. Epub 2011 Jun 29.

PMID:
21726628
6.

Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.

Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.

Gastroenterology. 2012 Mar;142(3):521-530.e3. doi: 10.1053/j.gastro.2011.11.023. Epub 2011 Nov 19.

PMID:
22108192
7.

Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.

Spänkuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K.

Oncogene. 2007 Aug 23;26(39):5793-807. Epub 2007 Mar 19.

PMID:
17369857
8.

Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.

Lee C, Fotovati A, Triscott J, Chen J, Venugopal C, Singhal A, Dunham C, Kerr JM, Verreault M, Yip S, Wakimoto H, Jones C, Jayanthan A, Narendran A, Singh SK, Dunn SE.

Stem Cells. 2012 Jun;30(6):1064-75. doi: 10.1002/stem.1081.

9.

Polo-like kinase 1: target and regulator of transcriptional control.

Martin BT, Strebhardt K.

Cell Cycle. 2006 Dec;5(24):2881-5. Epub 2006 Dec 15. Review.

PMID:
17172872
10.

p53-dependent repression of polo-like kinase-1 (PLK1).

McKenzie L, King S, Marcar L, Nicol S, Dias SS, Schumm K, Robertson P, Bourdon JC, Perkins N, Fuller-Pace F, Meek DW.

Cell Cycle. 2010 Oct 15;9(20):4200-12. Epub 2010 Oct 4.

11.

MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.

Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX.

BMC Cancer. 2012 Nov 14;12:519. doi: 10.1186/1471-2407-12-519.

12.

Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.

Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci Vitiani L, Todaro M, De Maria R, Zeuner A.

Stem Cells. 2012 Sep;30(9):1819-30. doi: 10.1002/stem.1163.

13.

Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells.

Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH, Lu AG.

Med Sci Monit. 2012 Jun;18(6):BR237-46.

14.

Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1).

Chang YC, Wu CH, Yen TC, Ouyang P.

J Biol Chem. 2012 Feb 3;287(6):4376-85. doi: 10.1074/jbc.M111.289108. Epub 2011 Dec 19.

15.

Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.

Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.

Cell Cycle. 2011 Apr 15;10(8):1303-11. Epub 2011 Apr 15.

PMID:
21436619
16.

 p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.

Sanhaji M, Kreis NN, Zimmer B, Berg T, Louwen F, Yuan J.

Cell Cycle. 2012 Feb 1;11(3):543-53. doi: 10.4161/cc.11.3.19076. Epub 2012 Feb 1.

PMID:
22262171
17.

Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK, Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S, Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D.

Clin Exp Metastasis. 2011 Dec;28(8):899-908. doi: 10.1007/s10585-011-9421-9. Epub 2011 Sep 21.

PMID:
21953073
18.

Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.

Stoica GE, Franke TF, Moroni M, Mueller S, Morgan E, Iann MC, Winder AD, Reiter R, Wellstein A, Martin MB, Stoica A.

Oncogene. 2003 Sep 11;22(39):7998-8011.

PMID:
12970748
19.

Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.

Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.

Anticancer Drugs. 2011 Jun;22(5):444-53. doi: 10.1097/CAD.0b013e32834513f4.

PMID:
21399492
20.

Targeting polo-like kinase 1 for cancer therapy.

Strebhardt K, Ullrich A.

Nat Rev Cancer. 2006 Apr;6(4):321-30. Review.

PMID:
16557283
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk